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The study of expressed proteins in neoplasia is under-
going a revolution with the advent of proteomic analy-
sis. Unlike genomic studies where individual changes
may have no functional significance, protein expression
is closely aligned with cellular activity. This perspective
will review proteomics as a method of detecting markers
of neoplasia with a particular emphasis on lung cancer
and the potential to sample the lung by exhaled breath
condensate (EBC). EBC collection is a simple, new, and
noninvasive technique, which allows sampling of lower
respiratory tract fluid. EBC enables the study of a wide
variety of biological markers from low molecular weight
mediators to macromolecules, such as proteins, in a
range of pulmonary diseases. EBC may be applied to
the detection of lung cancer where it could be a tool in
early diagnosis. This perspective will explore the poten-
tial of applying proteomics to the EBC from lung cancer
patients as an example of detecting potential biomar-
kers of disease and progression.
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BACKGROUND
Neoplasia is one of the major causes of premature morbidity
and mortality in the developed world, accounting for up to 12%
of all deaths.
1 Early detection is vital for the effective treatment
of many neoplasms, providing evidence to substantiate the
implementation of population-wide screening programs in the
hope of reducing the mortality and morbidity in a number of
these cancers. Lung cancer is an example of a neoplasm which
presents late but which could be cured by surgery if detected
early in the disease process. This review will therefore focus on
this disorder as an example of how novel methods have the
potential to facilitate early detection of cancers.
Lung cancer is a major cause of cancer-related death in
industrialized countries worldwide,
2 affecting the lives of
1.2 million people who are diagnosed with the disease each
year.
3 Nearly 170,000 men and women in the United States die
each year from lung cancer, accounting for nearly 25% of all
cancer deaths (Table 1).
4 The prognosis for lung cancer
patients is poor with 5-year survival rates being less than
10%.
5 Curative surgery is efficacious only for those patients
who are diagnosed sufficiently early in the disease process The
poor prognosis is explained by the fact that 50% of patients
already have distant metastases at diagnosis.
2 If lung cancer is
localized at the time of diagnosis and treated promptly by
surgery, the 5-year survival rate increases to 52%.
6
The benefits of early diagnosis have prompted research into
methods of screening for early stage lung cancer in high-risk or
smoking populations. Screening for other cancers such as
breast, colorectal, and cervical neoplasias have succeeded in
reducing mortality rates through the benefits of early detec-
tion.
7 However, less certainty exists about screening for other
neoplasms, including lung and prostate cancers.
8,9 There has
been increasing interest in using exhaled breath as a simple
tool for screening, diagnosing, and even monitoring diseases of
the airway, including lung cancer.
10,11 Changes in the protein
profile secreted into the lower respiratory tract may be detected
in exhaled breath condensate (EBC) of lung cancer patients as
an indication of the underlying neoplastic processes, present-
ing a potential screening tool for the early detection of lung
carcinomas.
Alternative or complimentary screening tools with the
potential to improve sensitivity are needed to demonstrate the
clinical significance of screening for lung cancer. Lung cancer
is an obvious neoplasm to target as the population at risk, i.e.,
smokers, is clearly defined. EBC may present a simple,
noninvasive, and more accurate alternative to the current lung
cancer screening technologies.
Proteins and Carcinogenesis
Understanding carcinogenesis, tumor progression, and metas-
tasis requires a careful analysis of effector molecules such as
proteins, which act as crucial components of the network of
signalling pathways that drive neoplasia.
12,13 Whereas carci-
nogenesis is usually because of genomic mutations, the
subsequent translational changes in the protein products
indicate both molecular mechanisms and potential markers
of neoplasia.
14 The interactions of proteins in an intricate
network determines the function of the organism and are
indicative of biological complexity downstream from the altera-
tions within the genes of the neoplastic cell. The detection of
protein patterns may be a method of interpreting signalling
pathways and other cellular processes that contribute to
cancer development and metastasis.
13 An increased under-
78standing of the functional role of proteins regulating key cell
processes will probably have a major impact on health out-
comes. Clinical proteomics is emerging as a new way to explore
those proteins regulating a variety of cellular activities within a
given type of cancer and within a specific cancer cell.
Proteomic Technologies
Proteomics may be defined as the large-scale characterization
of proteins expressed by the genome.
12 Unlike the study of a
single protein or pathway, proteomic methods enable a
systematic overview of expressed protein profiles, which, in
the case of neoplasia, ultimately could improve the diagnosis,
prognosis, and management of patients by revealing the
protein interactions affecting overall tumor progression.
13
Furthermore, differential protein expression analysis can be
used to compare neoplastic with normal tissue and is able to
indicate a range of protein markers potentially indicative of
disease.
4 It is highly likely that proteomics will signpost
candidate markers and indicate mechanisms that are in need
of greater analysis. Once identified, these individual markers
may become mundane single protein assays in clinical labora-
tories, similar to examples such as the prostate specific
antigen, carcinoembryonic antigen, and C-reactive protein.
14–17
Furthermore, individual cancer profiling could identify pathways
which have been activated and which are suitable for tailored
chemotherapeutic strategies to each individual neoplasm. The
human genome is considerably smaller than previously thought,
andinthispostgenomeprojectera,many of thegenesassociated
with tumorigenesis are now known. A smaller genome, however,
does not reflect a simple proteome. It is becoming apparent that
extensive posttranslational modifications such as phosphoryla-
tion, glycosylation, and proteolytic processing are common
events, which present a challenge for protein analysis. These
posttranslational modifications can significantly alter protein
functionandthusthe characteristicsofthe cellortissueinwhich
it is expressed. Thus, in the post genome era, one of the
challenges of proteomics is to understand the characteristics of
tissue through knowledge of effector proteins and to apply this to
clinical usage. Protein phenotypes are the determinants of the
characteristics of a particular cancer, which would not necessar-
ily be predicted by genomic analysis alone. Thus, proteomics has
the potential to contribute to understanding protein messengers
and to be applied to clinical usage.
Proteomics employs protein microarrays, electrophoresis,
and mass spectrometry for the detection, identification, and
characterization of proteins (Table 2).
4,13 These proteomic tools
have their own individual advantages and limitations affecting
their ability to assess the protein profile.
Protein microarrays use either multiple different capture
antibodies dotted separately on a slide (forward microarrays)
or multiple tissue/protein samples, again dotted and fixed on a
single slide (reverse microarrays). Whereas these methods can
detect the presence of numerous proteins or the level of
expression in multiple tissue samples, respectively, the tech-
nique is limited by the availability of specific and sensitive
antibodies, which, as an example, has proved to be an issue for
known lung cancer markers such as the cytokeratins. Fur-
thermore, antibody specificity must be validated by immuno-
blotting, and internal controls are required, particularly if the
antibodies in the microarray do not bind with predictable
affinity and specificity. Nevertheless, the continuing increase
in the number of commercially available antibodies makes the
clinical application of protein microarrays feasible. Detection of
low abundance proteins also remains a problem, and methods
for multiple protein amplifications, analogous to the polymer-
ase chain reaction for DNA, are being developed as arrays but
are not yet available.
18
One of the main methods for separating proteins before
mass spectrometry is gel electrophoresis. Gel electrophoresis
separates denatured proteins according to their molecular
weights. In addition, two-dimensional gels allow an extra
degree of resolution or separation of proteins based upon the
pH/pKa, which is particularly useful in separating proteins of
a similar molecular weight. Individual protein spots can be
stained and digested into peptides, which can be analyzed by
mass spectrometry. The peptide mass ‘fingerprint’ is then
matched with sequences from protein databases.
One of the key tools of proteomics is mass spectrometry
(MS). Mass spectrometers analyze proteins after their conver-
sion to gaseous ions, which can then be identified based on
mass to charge ratio. Desorption and ionization techniques
such as matrix-assisted laser desorption ionization (MALDI)-
MS (Table 2) offer very high levels of sensitivity and mass
accuracy for the detection and identification of proteins. The
sensitivity and ease of sample preparation makes this tech-
nique convenient but it is not without limitations. These
include difficulties detecting proteins larger than about
50 kDa and analysing complex samples such as serum. The
type of MS technique used can affect the interpretation of the
data retrieved, which should be analyzed by an experienced
operator, which can lead to an element of subjectivity.
Other limitations are intrinsic to biological samples undergo-
ing analysis. Differencesin protein expression between tumors of
different subtypes and stages (Table 1) may make interpretation
difficult, unlike genomic analysis, which tends to be more
constant. It is possible to use proteomics to distinguish between
subtypes and stages of lung neoplasia,
19,20 but for a screening
testtoberobust,itmustdistinguishaneoplasticprocessnotonly
from normal individuals but also from other nonmalignant
diseases, each of which are likely to have a unique protein profile
set. Furthermore, changes in protein expression and immuno-
logical capabilities occur during aging, which means that
appropriate age-matched control subjects need to be included.
Despite these inherent limitations,proteomicshas beensuccess-
fulindetectingsignificantchangesinproteinprofilesinanumber
of biological samples associated with the development of a range
of neoplasia.
Table 1. Histopathological Classification of Lung Cancer and
Approximate Proportions (adapted from Kumar et al.
2)
Classification of lung cancer Approximate
proportions (%)
Nonsmall cell lung carcinoma (NSCLC) 70–75
Squamous cell carcinoma 25–30
Adenocarcinoma, including
bronchoalveolar carcinoma
30–35
Large cell carcinoma 10–15
Small cell lung carcinoma (SCLC) 20–25
Combined patterns 5–10
Mixed squamous cell carcinoma
and adenocarcinoma
Mixed squamous cell carcinoma and SCLC
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Method Principle Advantages Disadvantages
Electrophoresis
Electrophoresis When an electric field is applied to a
solution containing a protein
that has a net positive or negative
charge, the protein migrates at a
rate that depends on its net
charge, size, and shape.
Gels must be stained before
proteins can be visualized.
Rarely useful by itself as proteins
cannot be accurately identified
without the use of another
detection technique such as
immunoblotting or mass
spectroscopy.
SDS-PAGE Proteins migrate through inert
matrix gel of polyacrylamide. Pore
size is adjustable to retard protein
of interest. SDS is a negatively
charged detergent that unfolds
proteins and frees them from other
molecules. Proteins migrate at
different rates toward positive
electrode.
Separates all types of proteins,
even those insoluble in water.
One-dimensional separation
method has limited resolution.
Closely spaced bands or peaks
tend to overlap. Can only resolve
a small number of proteins.
Two-dimensional
gel electrophoresis
Combines 2 separation
procedures. First dimension: the
solubilized, denatured proteins are
separated by their isoelectric point
(pH where net charge is 0) in
a polyacrylamide gel. Second
dimension: the narrow gel
containing proteins separated by
isoelectric focusing undergoes
electrophoresis at a right angle in
SDS-PAGE to separate by size.
Good resolution of mixture.
Comparison of multiple gels
facilitated by image analysis
software. Posttranslational
modifications can be
discerned. Resolution of
protein approximately
1 ng/mL.
Presence of high abundance
proteins (i.e., albumin,
immunoglobulins) may obscure
low abundance proteins. Low
throughput. Final identification
of protein requires spot removal
from gel, digestion, and analysis
of peptides by mass spectrometry.
Unable to resolve low molecular
weight proteins (<10,000 Da). Not
easily amenable to multivariate
analysis.
Two-dimensional
fluorescence
difference gel
electrophoresis
Labels complex mixtures with
fluorescent dyes before
conventional two-dimensional
electrophoresis. Different cyanine
dyes are used to label protein from
different samples and will be
excited and emit at different light
wavelengths. Up to three different
samples can be labeled and mixed
together (test, control, reference).
Analysis of differences between
mixtures is simplified. Ratio
of protein expression can be
obtained in a single gel, and
an internal standard can be
used in each gel to reduce
gel-to-gel variation. Very
sensitive.
Presence of high abundance
proteins (i.e., albumin,
immunoglobulins) may obscure
low abundance proteins. Low
throughput. Final identification
of protein requires spot removal
from gel, digestion, and analysis
of peptides by mass spectrometry.
Many spots cannot be identified
because of lack of material.
Unable to resolve low molecular
weight proteins (<10,000 Da).
Protein array
Protein
arrays
Multiplex protein
arrays, cytokine
arrays, tissue
microarrays
In most common form, antibodies to
known proteins are tethered to a
surface (beads, nitrocellulose, etc.)
and then detected using
principles of immunoassays.
High sensitivity and
throughput. Multiple
analytes can be measured
simultaneously.
Identification of potential
targets already known.
Limited antibody availability and
specificity. Required some prior
knowledge of expressed proteins.
May not detect isoforms of
analyte. Cost per sample may be
prohibitive.
Mass spectroscopy (MS)
MS Matrix-assisted
laser desorption
ionization time-
of-flight mass
spectrometry
(MALDI-TOF-
MS)
Determines the precise mass of
protein or peptide fragment from
protein. Protein/peptide samples
are mixed with organic acid matrix,
dried on metal slide, and blasted by
laser ionizing the peptide, which
is accelerated in an electric field
toward a detector. The time it takes
to reach the detector is determined
by the charge and mass. Peptide
sequence information can be
obtained with tandem mass
spectrometers (MS–MS).
Highest resolution is for
molecules <3,000 Da in size.
(continued on next page)
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Using protein microarrays, it has been possible to demonstrate
significant differences in the serum protein profile of lung
cancer patients when compared with healthy controls and
subjects with chronic obstructive pulmonary disease (COPD).
21
Two-dimensional gel electrophoresis in conjunction with MS
detected a greater than twofold difference in specific serum
proteomic profiles between lung cancer patients and healthy
volunteers.
22 Proteomics has been used to define tumor subsets
in resected lung specimens and has been demonstrated to
distinguish primary adenocarcinomas from primary squamous
cell carcinomas with 98% accuracy.
20 In addition to lung cancer,
proteomics has beenappliedto the early detection and treatment
of cancers of the ovary, pancreas, prostate, esophagus, breast,
liver, and rectum.
23,24 For example, plasma surface-enhanced
laser desorption/ionization (SELDI)-MS discriminated pancreat-
ic cancer patients from healthy controls with a sensitivity of
97.2% and a specificity of 94.4%.
25 In addition, SELDI-MS
identified significant differences in protein peaks in the plasma
of controls and women with ovarian cancer.
26
Thus, proteomic techniques could play a role in the early
detection of neoplasia, by the analysis of samples such as
plasma, but could also play a role in identifying particular
tumor pathways, which could be targeted for chemotherapy,
leading to a unique profile for each person’s neoplasm. In
addition, single markers could be identified for monitoring
clinical response to treatment.
A note of caution needs to be made to temper the enthusi-
asm for applying these techniques. The reproducibility of
SELDI-MS both within and between studies may be subopti-
mal from which to draw conclusions in terms of biomarkers
and can be somewhat insensitive, particularly when estab-
lished tumor markers are not identified.
27,28 These constraints
demonstrate the need for studies of reproducibility and
applicability to be undertaken. In addition, problems of over-
fitting (an apparent discriminatory pattern, which occurs by
chance) and poor validation of the proposed markers that have
been identified can be an issue also.
29
Screening for Lung Cancer
Sputum cytology, interval chest x-rays, and to date, computed
tomography (CT) scans as population screening tools in
smokers and ex-smokers have failed to show improved lung
cancer mortality rates.
30 For a screening tool to be successful,
the intervention should reduce mortality, and furthermore, the
sensitivity, specificity, availability, and cost together with the
associated morbidity of the screening tests must be reason-
able. Whereas chest x-rays combined with sputum cytology
can detect early stage lung cancers, disappointingly no overall
improvement in mortality was observed.
27–29,31–33 Recently,
interval thoracic CT as a screening tool for lung cancer has
been shown to detect nodules of much smaller diameter
compared to those detected by plain chest x-ray (3 vs
<0.5 cm) and refinements in helical CT have reduced scanning
time and radiation dose. Although preliminary results suggest
80–90% of CT screening-detected bronchial carcinomas are
diagnosed as stage 1 tumors,
31,34 up to 60% of all lesions
detected are found to be benign with morbidity and mortality
associated with the subsequent biopsies. CT may create lead-
time bias where early diagnosis appears to prolong survival
falsely, and clearly leads to overdiagnosis and unnecessary
surgical procedures.
35 These are important issues that will
only be resolved by large-scale trials and are discussed in more
detail for the interested reader at http://www.ahrq.gov/clinic/
uspstf/uspslung.htm.
EXHALED BREATH CONDENSATE
EBC collection is a simple, safe, comfortable, and completely
noninvasive method of sampling the lower respiratory tract in
humans.
36,37 Exhaled breath enters a collection system, is
Table 2. (continued)
Method Principle Advantages Disadvantages
Surface-enhanced
laser desorption/
ionization time-
of-flight mass
spectrometry
(SELDI-TOF-MS)
Comparable to MALDI, the
difference being that SELDI uses
chromatographic chip arrays to
selectively bind subsets of
proteins from complex samples. The
surfaces can be washed to remove
nonspecifically bound proteins and
substances that can interfere with
the ionization process (salt,
detergents, etc.).
High throughput via
automation. Requires
minimal sample preparation.
Can be combined with
prefractionation of material
to enhance the detection of
lower abundant proteins.
No direct identification of proteins.
Less sensitive to high molecular
weight protein (>20 kDa). May
have instrument-to-instrument
variation.
Stable isotope
labeling
Biological samples are labeled with
different stable isotopes using
modifying agents targeting a specific
amino acid (e.g., ICAT). After
separation and mass spectrometry,
peptides from the 2 samples
differing in mass units specific for
the isotope used (e.g., 8-Da mass
shift for ICAT) can then be
used to provide relative
quantification.
Wider proteome coverage than
other methods. Can obtain
quantitative information on a
large number of proteins;
Usually yields IDs of relevant
proteins.
Technically demanding; very low
throughput capability; samples
need to be trypsinized before
analysis; reliable quantitative
measurements likely on most
abundant proteins.
Adapted from Hoehn and Suffredini.
12
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vapor to condense.
38 The condensate contains a range of
nonvolatile substances,
39 including macromolecules such as
proteins.
40–42 Its potential as a diagnostic tool for a range of
lung diseases has provoked research into applying this method
as a possible screening tool for the early detection of lung
cancer.
43 Unlike traditional methods of sampling secretions
from the lower respiratory tract such sputum induction and
bronchoalveolar lavage, EBC is noninvasive, does not disturb
the underlying disease process, and can be repeated within a
short period of time, even in asthmatic patients (Fig. 1).
38
Collection of EBC
Standardization of EBC collection has yet to occur and leads to
differences when comparing reports, as many studies have
used a variety of condenser designs.
11,36,38,44 A degree of
variability in repeated samples, even when using a commercial
breath condenser,
45 has led to published recommendations for
collection methods and equipment.
36 More research is re-
quired before a particular device can be recommended for
protein detection. The optimum cooling temperature remains
unclear, and although there is an expectation that colder
conditions would be more efficient, this is unproved.
36 Dry ice,
liquid nitrogen, and refrigerated units attain lower collection
temperatures (−20°C),
46 however, devices using wet ice have
been able to obtain samples of proteins with condensing
chambers reaching temperatures of 1–2°C
47–50 (Conrad 2006,
unpublished observations).
The collection of EBC involves normal, relaxed tidal breath-
ing.
39 Most studies suggest 10 minutes as the minimum
duration of collection, although some used longer time peri-
ods.
11,36,48 The volume of condensate collected is largely
dependant on the breath volume and hydration status of
individual patients, as well as the different temperatures and
materials used by the different condensing systems.
46,49,50 In
order for the EBC to reflect the composition of the lining of the
lower airways accurately, upper airway contaminants need to
be kept to a minimum. Oral breathing, mouth rinsing,
voluntary swallowing of saliva, and a saliva trap may decrease
contamination.
11,36,39 Samples should be immediately frozen
at −70°C to inactivate any proteases.
36 The addition of
protease inhibitors may further prevent degradation of pro-
teins, however, protease inhibitors can interfere with protein
analysis. Storage under argon will avoid oxidization of pro-
teins,
51 and storage in polyethylene tubes will minimize
protein adhesion. The measurement and identification of
proteins in EBC remains an area where increasing standard-
ization will be required as the amount of protein varies even in
healthy individuals (between 4 and 1.4 mg/mL).
52 The time of
day of collection, type and amount of food and drink consumed
before collection, tobacco smoking, medications, and presence
of systemic diseases are some of the unknown factors that may
affect EBC protein analysis.
36 As the effects are unknown,
researchers should detail these variables to control for these
potential sources of error, and ideally, samples should be
collected after a period of fasting.
Application of Proteomics to EBC and Lung
Cancer
Specific proteins have been identified in EBC that may act as
significant markers of lung cancer. For example, endothelin-1
and interleukin-6 were both found to be increased in the EBC
of nonsmall cell lung cancer patients when compared with
healthy controls.
42,53 Studies on serum or tumor samples from
lung cancer patients have demonstrated that distinct mass
profile signatures can be detected using SELDI-MS technology
but the identity of the proteins requires further processing and
the results need further confirmation in other studies.
54,55
Despite the ability to detect proteins in EBC, there has been
no published research documenting the use of proteomics to
identify differences between the EBC protein profiles of lung
cancer patients and healthy controls. Biological samples
relating to lung cancer to which proteomics has been applied
include plasma, serum, bronchoalveolar lavage, and surgically
resected specimens.
4 Analysis of EBC proteins has been
restricted to specific proteins,
42,53 or measuring total protein
concentration.
40,41,45
CONCLUSIONS
Proteomics has provided a significant body of evidence sup-
porting the concept of protein profiling to pinpoint biomarkers
Figure 1. An example of a simple exhaled breath condensing device. A one-way valve allows air to be inspired and the exhaled breath to
be cooled using ice or another cooling system, e.g., dry ice or a refrigerated circuit. The conditions (e.g., temperature) and types of materials
used in EBC collection can influence the amounts and types of markers captured.
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biological samples. Currently, these proteomic techniques are
commonly used in the research laboratory, but have yet to
become commonplace in the clinical laboratory. Their applica-
tion to EBC could provide clinicians with a panel of markers as
a simple, noninvasive, specific, and sensitive screening tool for
the early detection of lung carcinomas. Despite this promising
line of inquiry, a number of obstacles remain. It is not yet
known if EBC contains enough proteins to be able to create the
profile that will significantly differ from those of normal
controls or other pulmonary diseases. EBC collection and the
tools of proteomics in detecting proteins have still not been
perfected, and unknown confounding variables may interfere
with protein analysis. Whereas more research is needed before
this technique can be applied in the clinical setting for the
early detection of lung carcinomas or as a way of identifying
tumor subtypes, it is a rapidly growing subject which will be
producing interesting results for years to come.
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